Melissa A Polusny1, Mandy J Kumpula2, Laura A Meis3, Christopher R Erbes4, Paul A Arbisi5, Maureen Murdoch3, Paul Thuras4, Shannon M Kehle-Forbes3, Alexandria K Johnson6. 1. Minneapolis VA Health Care System, Minneapolis, MN, USA; Center for Chronic Disease Outcomes Research, Minneapolis, MN, USA; Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA. Electronic address: melissa.polusny@va.gov. 2. Minneapolis VA Health Care System, Minneapolis, MN, USA; Department of Psychology, Northern Illinois University, DeKalb, IL, USA. 3. Minneapolis VA Health Care System, Minneapolis, MN, USA; Center for Chronic Disease Outcomes Research, Minneapolis, MN, USA; Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA. 4. Minneapolis VA Health Care System, Minneapolis, MN, USA; Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA. 5. Minneapolis VA Health Care System, Minneapolis, MN, USA; Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA; Department of Psychology, University of Minnesota, Minneapolis, MN, USA. 6. Minneapolis VA Health Care System, Minneapolis, MN, USA; Center for Chronic Disease Outcomes Research, Minneapolis, MN, USA.
Abstract
OBJECTIVE: Although women in the military are exposed to combat and its aftermath, little is known about whether combat as well as pre-deployment risk/protective factors differentially predict post-deployment PTSD symptoms among women compared to men. The current study assesses the influence of combat-related stressors and pre-deployment risk/protective factors on women's risk of developing PTSD symptoms following deployment relative to men's risk. METHOD: Participants were 801 US National Guard Soldiers (712 men, 89 women) deployed to Iraq or Afghanistan who completed measures of potential risk/protective factors and PTSD symptoms one month before deployment (Time 1) and measures of deployment-related stressors and PTSD symptoms about 2-3 months after returning from deployment (Time 2). RESULTS: Men reported greater exposure to combat situations than women, while women reported greater sexual stressors during deployment than men. Exposure to the aftermath of combat (e.g., witnessing injured/dying people) did not differ by gender. At Time 2, women reported more severe PTSD symptoms and higher rates of probable PTSD than did men. Gender remained a predictor of higher PTSD symptoms after accounting for pre-deployment symptoms, prior interpersonal victimization, and combat related stressors. Gender moderated the association between several risk factors (combat-related stressors, prior interpersonal victimization, lack of unit support and pre-deployment concerns about life/family disruptions) and post-deployment PTSD symptoms. CONCLUSIONS: Elevated PTSD symptoms among female service members were not explained simply by gender differences in pre-deployment or deployment-related risk factors. Combat related stressors, prior interpersonal victimization, and pre-deployment concerns about life and family disruptions during deployment were differentially associated with greater post-deployment PTSD symptoms for women than men.
OBJECTIVE: Although women in the military are exposed to combat and its aftermath, little is known about whether combat as well as pre-deployment risk/protective factors differentially predict post-deployment PTSD symptoms among women compared to men. The current study assesses the influence of combat-related stressors and pre-deployment risk/protective factors on women's risk of developing PTSD symptoms following deployment relative to men's risk. METHOD:Participants were 801 US National Guard Soldiers (712 men, 89 women) deployed to Iraq or Afghanistan who completed measures of potential risk/protective factors and PTSD symptoms one month before deployment (Time 1) and measures of deployment-related stressors and PTSD symptoms about 2-3 months after returning from deployment (Time 2). RESULTS:Men reported greater exposure to combat situations than women, while women reported greater sexual stressors during deployment than men. Exposure to the aftermath of combat (e.g., witnessing injured/dying people) did not differ by gender. At Time 2, women reported more severe PTSD symptoms and higher rates of probable PTSD than did men. Gender remained a predictor of higher PTSD symptoms after accounting for pre-deployment symptoms, prior interpersonal victimization, and combat related stressors. Gender moderated the association between several risk factors (combat-related stressors, prior interpersonal victimization, lack of unit support and pre-deployment concerns about life/family disruptions) and post-deployment PTSD symptoms. CONCLUSIONS: Elevated PTSD symptoms among female service members were not explained simply by gender differences in pre-deployment or deployment-related risk factors. Combat related stressors, prior interpersonal victimization, and pre-deployment concerns about life and family disruptions during deployment were differentially associated with greater post-deployment PTSD symptoms for women than men.
Authors: Karen S Mitchell; Erika J Wolf; Michelle J Bovin; Lewina O Lee; Jonathan D Green; Raymond C Rosen; Terence M Keane; Brian P Marx Journal: J Abnorm Psychol Date: 2017-02-13
Authors: Gregory H Cohen; Laura A Sampson; David S Fink; Jing Wang; Dale Russell; Robert Gifford; Carol Fullerton; Robert Ursano; Sandro Galea Journal: Womens Health Issues Date: 2016-02-18
Authors: Melissa A Polusny; Craig A Marquardt; Emily Hagel Campbell; Clarissa R Filetti; Valentin V Noël; Seth G Disner; Jonathan D Schaefer; Nicholas Davenport; Shmuel Lissek; Siamak Noorbaloochi; Scott R Sponheim; Christopher R Erbes Journal: Res Hum Dev Date: 2021-09-22
Authors: Nikki R Wooten; Rachel Sayko Adams; Beth A Mohr; Diana D Jeffery; Wendy Funk; Thomas V Williams; Mary Jo Larson Journal: Adm Policy Ment Health Date: 2017-07
Authors: Brian N Smith; Avron Spiro; Susan M Frayne; Rachel Kimerling; Yasmin Cypel; Matthew J Reinhard; Amy M Kilbourne; Kathryn M Magruder Journal: Psychosom Med Date: 2020 Feb/Mar Impact factor: 4.312